FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “PSYC Acquires Domains Relevant to Psychedelic Industry Providing Strategic Advantage for Industry Growth.”
Global Trac Solutions, Inc. (OTC: PSYC) is pleased to announce that PSYC has purchased over 25 psychedelic-related domains, which the Company intends to strategically utilize over the next several months as part of its objective to emerge as one of the first and most reliable resources in the budding sector of psychedelic medicine and treatments.
Global Trac Solutions is a diversified holding company dedicated to identifying new and emerging industries. By utilizing our years of business development expertise our diverse team of innovators continuously leverages our experience to effectively execute go-to-market strategies in order to position ourselves for rapid growth through the creation of an evolving business foundation to enhance profitability potential.
The current pandemic has caught people and the healthcare systems off guard; the measures taken, such mandatory quarantines and social distancing, do have side effects. According to Mailman School of Public Health at Columbia University, the 2003 SARS outbreak led to significant increases in depression and post-traumatic stress disorder (PTSD) among caregivers, those quarantined and people affected in other ways. In recent years, the rise of the cannabis industry, and the prevalence of the medical products that came with it, led to a steep increase in use among the health-conscience youth. For example, research published by New Frontier Data late last year indicates that CBD products were used for many reasons, but chief among them were for medical purposes, from inflammation (8.5%) to anxiety (7.1%) or depression (4.4%). Following the steps of the cannabis industry, psychedelic products for medical applications are now entering the fray. Global Trac Solutions Inc. (OTC: PSYC), Mind Medicine (MindMed) Inc. (OTC: MMEDF) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Auxly Cannabis Group Inc. (OTC: CBWTF) (TSX-V: XLY), Charlotte’s Web Holdings, Inc. (OTC: CWBHF) (TSX: CWEB)
The naturally occurring psychedelic prodrug compound psilocybin, which is produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms, has taken on a similar path to the legalization of cannabis. This is because several crucial data points have been observed in recent studies, pointing to potential benefits of such products. For example, according to a 2020 study from the Journal of Psychopharmacology, a single dose of psilocybin can make symptoms of depression significantly improve. The randomized controlled trial compared single-dose psilocybin with single-dose niacin in conjunction with psychotherapy in participants with cancer-related psychiatric distress. “Results suggested that psilocybin-assisted psychotherapy facilitated improvements in psychiatric and existential distress, quality of life, and spiritual well-being up to seven weeks prior to the crossover. Participants overwhelmingly (71-100%) attributed positive life changes to the psilocybin-assisted therapy experience and rated it among the most personally meaningful and spiritually significant experiences of their lives.”
For more information, please visit: Global Trac Solutions, Inc.
For more corporate news on Global Trac Solutions, Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.